Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of DTRI-031 in Healthy Volunteers
NCT05005520Phase 1Completed
- Sponsor
- Basking Biosciences
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ischemic stroke comparing DTRI-031 with Placebo (2 arms). Primary endpoint: Adverse Events. Started Oct 2021; status: completed.
02
Drugs
BB-031
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05005520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005520.